For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

USPTO Granted Patents = 26

CIPO Patents = 1

EPO Patents = 8

Trademarks = 12

Forward Citations = 188

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Cedric Francois (24 out of 41 patents)

Pascal Deschatelets (23 out of 31 patents)

Federico Grossi (5 out of 5 patents)

4. Patrick Johnson (4 out of 4 patents)

5. Carolina Vega (4 out of 4 patents)

6. Monica Gerber (3 out of 4 patents)

7. Paul Olson (3 out of 24 patents)

8. Lukas Scheibler (2 out of 17 patents)

9. Christian Mueller (2 out of 23 patents)

10. Zhouning Zhang (1 out of 1 patent)

26 patents: Sort by Forward Citations

1. 12458695 - Dosing regimens and related compositions and methods (2025-11-04),

2. 12290566 - Dosing regimens and related compositions and methods (2025-05-06),

3. 12251395 - RNAS for complement inhibition (2025-03-18),

4. 11903994 - Dosing regimens (2024-02-20),

5. 11844841 - Dosing regimens and related compositions and methods (2023-12-19),

6. 11712460 - Methods of treating chronic disorders with complement inhibitors (2023-08-01),

7. 11661441 - Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof (2023-05-30),

8. 11510939 - RNAs for complement inhibition (2022-11-29),

9. 11407789 - Cell-penetrating compstatin analogs and uses thereof (2022-08-09),

10. 11338013 - Combination therapy for C3 inhibition (2022-05-24),

11. 11292815 - Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods (2022-04-05),

12. 11291407 - Detection of high risk drusen (2022-04-05),

13. 11040107 - Dosing regimens and related compositions and methods (2021-06-22),

14. 11013782 - Methods of treating chronic disorders with complement inhibitors (2021-05-25),

15. 11001610 - Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof (2021-05-11),

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the development and commercialization of novel therapeutic compounds for the treatment of various diseases. With a strong emphasis on immunology and complement biology, Apellis aims to address unmet medical needs and improve patient outcomes. The company is committed to bringing innovative medicines to market that have the potential to make a significant impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

26 Patents

#50 in Waltham, MA

#750 in Massachusetts

#12,455 in US

#24,104 in the World

Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

Forward Citations = 188

10 inventors:

Cedric Francois (24 out of 41 patents)

Pascal Deschatelets (23 out of 31 patents)

Federico Grossi (5 out of 5 patents)

4. Patrick Johnson (4 out of 4 patents)

5. Carolina Vega (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…